
Zymeworks Inc is a biotechnology business based in the US. Zymeworks shares (ZYME) are listed on the NYSE and all prices are listed in US Dollars. Zymeworks employs 327 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Zymeworks
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ZYME – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Zymeworks stock price (NYSE: ZYME)
Use our graph to track the performance of ZYME stocks over time.Zymeworks shares at a glance
Latest market close | $5.54 |
---|---|
52-week range | $4.56 - $38.63 |
50-day moving average | $5.96 |
200-day moving average | $13.18 |
Wall St. target price | $24.45 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-4.97 |
Buy Zymeworks shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Zymeworks stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Zymeworks price performance over time
Historical closes compared with the close of $5.54 from 2022-07-01
1 week (2022-06-27) | -9.48% |
---|---|
1 month (2022-06-01) | -20.63% |
3 months (2022-03-31) | N/A |
6 months (2021-12-31) | -66.20% |
1 year (2021-07-02) | -84.81% |
---|---|
2 years (2020-07-02) | -84.60% |
3 years (2019-07-03) | 23.16 |
5 years (2017-07-03) | 8.28 |
Zymeworks financials
Revenue TTM | $28 million |
---|---|
Gross profit TTM | $-172,859,000 |
Return on assets TTM | -33.15% |
Return on equity TTM | -72.74% |
Profit margin | 0% |
Book value | $4.89 |
Market capitalisation | $320.1 million |
TTM: trailing 12 months
Zymeworks share dividends
We're not expecting Zymeworks to pay a dividend over the next 12 months.
Zymeworks share price volatility
Over the last 12 months, Zymeworks's shares have ranged in value from as little as $4.56 up to $38.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zymeworks's is 1.0485. This would suggest that Zymeworks's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Zymeworks overview
Zymeworks Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd. ; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd. ; Daiichi Sankyo Co. , Ltd.
Zymeworks in the news
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer

Drug developer Zymeworks adopts 'poison pill' to keep All Blue at bay
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
Frequently asked questions
What percentage of Zymeworks is owned by insiders or institutions?Currently 7.114% of Zymeworks shares are held by insiders and 89.175% by institutions. How many people work for Zymeworks?
Latest data suggests 327 work at Zymeworks. When does the fiscal year end for Zymeworks?
Zymeworks's fiscal year ends in December. Where is Zymeworks based?
Zymeworks's address is: 114 East 4th Avenue, Vancouver, BC, Canada, V5T 1G4 What is Zymeworks's ISIN number?
Zymeworks's international securities identification number is: CA98985W1023 What is Zymeworks's CUSIP number?
Zymeworks's Committee on Uniform Securities Identification Procedures number is: 98985W102
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert